FIELD: medicine.
SUBSTANCE: group of inventions is based on application of chemokine receptor CCR4 as marker for cancer identification and/or staging. information of diagnostic type is obtained by measurement of levels of CCR4, expressed by epithelial tumour cells in sample of patient's solid or non-hematological cancer. Group of inventions also relates to application of oligonucleotide primer or probe, capable of hybridisation under stringent conditions with SEQ ID NO:1, for identification of presence or measurement of quantity of CCR 4 expression by epithelial cells of solid tumour or non-hematological tumour.
EFFECT: application of group of inventions makes it possible to diagnose or stage cancer in more precise and reliable way.
37 cl, 22 dwg, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR CLASSIFYING PATIENTS WITH SOLID CANCER | 2017 |
|
RU2745730C2 |
| I-3859 ANTIBODY APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636032C2 |
| ANTI-IL1RAP ANTIBODIES AND THEIR USE FOR TREATING HUMAN | 2012 |
|
RU2597831C2 |
| ANTITUMOUR AGENT | 2014 |
|
RU2667644C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2694903C1 |
| COMBINATION OF POXVIRUS ENCODING HUMAN PAPILLOMA VIRUS POLYPEPTIDES, AND IL-2 WITH ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824962C1 |
| NEW ANTIBODY TO CXCR4 AND ITS APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636345C2 |
| REPRODUCTION AND USE OF NON-HEMATOPOIETIC TISSUE-RESIDENT γδ T-CELLS | 2016 |
|
RU2784566C2 |
| TREATING MALIGNANT TUMOURS USING MODULATORS OF PI3-KINASE ISOFORMS | 2013 |
|
RU2702908C2 |
